Moderna Inc

Moderna insiders’ massive option and RSU grants signal bullish confidence amid soaring mRNA vaccine momentum and a 111% year‑to‑date surge, boosting investor optimism for future growth.

Moderna insider buying surge: Sandra Horning’s 16,233‑share purchase signals bullish confidence in the company’s mRNA pipeline and revenue growth.

Moderna insider trades reveal a steady, long‑term buy‑hold stance, with executive purchases reflecting confidence in the mRNA platform and a bullish outlook.

Moderna’s chief legal officer buys shares after a $2.25 billion patent settlement—showing executive confidence and a clearer IP path for future mRNA growth.

Moderna CEO Stéphane Bancel’s March 1, 2026 buy of 250,932 shares signals steady insider confidence amid a mRNA rally and upcoming approvals.

Moderna CFO’s 2026 stock sale shows routine tax‑liquidation, not a sell‑off, underscoring insider moves as context rather than market signals.

Moderna CEO Stéphane Bancel’s recent PSU vesting boosts his stake by ~2 %—a bullish sign of leadership confidence amid regulatory setbacks and future mRNA pipeline growth.